ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: INFO28

C-PROBE Cohort: Longitudinal Deep Phenotyping of Patients with Chronic Kidney Disease

Session Information

Category: Glomerular Diseases

  • No subcategory defined

Authors

  • Bitzer, Markus, University of Michigan, Ann Arbor, Michigan, United States
  • Pennathur, Subramaniam, University of Michigan, Ann Arbor, Michigan, United States
  • Brosius, Frank C., The University of Arizona Health Sciences, Tucson, Arizona, United States
  • Bhat, Zeenat Yousuf, Wayne State University, Detroit, Michigan, United States
  • Massengill, Susan F., Levine Children's Hospital, Charlotte, North Carolina, United States
  • Bragg-Gresham, Jennifer L., University of Michigan, Ann Arbor, Michigan, United States
  • Lienczewski, Chrysta C., University of Michigan, Ann Arbor, Michigan, United States
  • Ju, Wenjun, University of Michigan, Ann Arbor, Michigan, United States
  • Gadegbeku, Crystal A., Temple University, Philadelphia, Pennsylvania, United States
  • Gipson, Debbie S., University of Michigan, Ann Arbor, Michigan, United States
  • Kretzler, Matthias, University of Michigan, Ann Arbor, Michigan, United States

Group or Team Name

  • C-PROBE Investigator Group
Description

The Clinical Phenotyping and Biobank Core (C-PROBE) was established in 2008 as part of the NIDDK funded O’Brien Kidney Center and provides longitudinal patient data and biological specimens from adult and pediatric patients with chronic kidney disease (CKD) recruited from five sites across the U.S. Demographic and clinical data and biospecimens are collected annually. Information includes household income, educational level, and standard routine lab results among others. Archived specimens include remnant tissue from indication kidney biopsies, plasma, serum, urine, and DNA. Extraction of data from the electronic health record is possible and biosamples are suitable for genomic, transcriptomic, proteomic and metabolomic analysis.
C-PROBE has enrolled 1732 patients, including 275 children and 1457 adults. 52% of all patients are female, 1% American Indian/Alaskan Native, 3% Asian/Asian American, 39% Black/African American, 52% Caucasian/White, 3% multiracial and 1% not reported; 9% self identify as Hispanic. Disease etiology breakdown is 48% glomerular, 16% diabetic kidney disease, 11% tubule-interstitial, 5% hypertension, 4% congenital anomalies of the kidney and urinary tract (CAKUT), and 16% hereditary/other. 641 patients (547 adult) have ≥ 3 eGFR data. 189 adult patients have reached the composite endpoint of end stage of kidney disease (ESRD) or 40% reduction of baseline eGFR. In addition, other parameters including cardiovascular events (coronary artery disease, acute coronary syndrome, peripheral vascular disease, stroke, congestive heart failure, arrhythmias) are captured during the follow-up period. Whole slide image analysis for digital histopathology analysis is available for kidney biopsy tissue.
Molecular (genomic, transcriptomic, proteomic and metabolomic) and digital histopathology data derived from patients’ samples have contributed to deep understanding of kidney pathophysiology and improved patient care, have directly contributed to several successful NIH grants, including K08, K01, R01 and R24, and publications in high impact journals including J Clin Invest, Sci Transl Med, J Am Soc Nephrol. and Kidney Int. Data and samples are available to investigator initiated studies.

Funding

  • In the past C-PROBE has been supported by the NIH/NIDDK; It is now funded by the Renal Pre-Competitive consortium (RPC2)